Right-of-use assets The Group principally has leases for plasma centres, office buildings, land, manufacturing facilities and warehouses. Except for short-term leases and leases of low value assets, the Group recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). The Group accounting policy for lease liabilities has been disclosed in Note 11(d). Unless the Group is reasonably certain to obtain ownership of the underlying asset at the end of the lease term, the recognised right-of-use assets are depreciated on a straightline basis over the shorter of its estimated useful life and the lease term. Other arrangements CSL has leased a recombinant protein facility in Lengnau to Thermo Fisher Scientific (TFS), which has a 20 year termwith two five year extension options. The lease has been accounted for as an operating lease and the leased property, plant and equipment continue to be presented in the balance sheet. The total future operating lease payments due from TFS (excluding extension options and variable lease payments) were $448m as at 30 June 2023 (2022: $454m). Plant and Equipment US$m Right-of-use assets US$m Capital work in progress US$m Total US$m 2023 2022 2023 2022 2023 2022 2023 2022 4,900 4,078 2,134 1,849 2,771 3,082 12,820 11,461 (2,378) (2,116) (579) (557) – – (3,468) (3,152) 2,522 1,962 1,555 1,292 2,771 3,082 9,352 8,309 1,962 1,667 1,292 1,102 3,082 3,628 8,309 7,537 789 615 – – (1,370) (1,550) – – 24 9 372 301 1,065 1,084 1,472 1,397 68 – 40 – 18 – 219 – (11) (4) (26) – – (2) (90) (12) (297) (277) (102) (90) – – (490) (445) – – – – – (13) – (13) (13) (48) (21) (21) (24) (65) (68) (155) 2,522 1,962 1,555 1,292 2,771 3,082 9,352 8,309 CSL Limited Annual Report 2022/23 137
RkJQdWJsaXNoZXIy MjE2NDg3